Clinical Use of Extracellular Vesicles in the Management of Male and Female Pattern Hair Loss: A Preliminary Retrospective Institutional Review Board Safety and Efficacy Study

Gordon H. Sasaki, MD, FACS

Abstract

Background: Pattern hair loss is a common disorder in female and male patients.

Objectives: To assess the safety, efficacy, and satisfaction of a single extracellular vesicle (EV) treatment over 6 months.

Methods: A retrospective open-label study among 22 female and 9 male patients who demonstrated early stages of alopecia or were in remission from previous medical and surgical treatments. The amount of undiluted or diluted volumes of EV solution used was determined by the extent and degree of alopecia. Global photography, Patient Global Aesthetic Improvement Scale (PGAIS) and Investigator Global Aesthetic Improvement Scale (IGAIS) questionnaires, and trichoscan measurements were compared at baseline and 6 months in 3 response categories.

Results: Frequent growth responses were observed: older aged females and younger aged males, shorter history of alopecia, earlier stages of hair loss, larger and undiluted volumes of XoFlo, previous positive responses to medical and surgical treatments, and absence or control of disease factors affecting the hair. Global photography, trichoscan for density, follicle diameter, terminal: vellus ratio, and PGAIS/IGAIS satisfaction questionnaires at baseline and 6 months were useful in assessing clinical efficacy. No significant adverse reactions were observed.

Conclusions: Intradermal injections with varying doses of EVs were safe and effective among indicated alopecic female and male patients. Findings suggest that the presence of positive factors, absence of conditions known to negatively affect hair growth, and administration of larger volumes of XoFlo may have a significant influence on the use of this new cell-free therapy.

Level of Evidence: 4

Editorial Decision date: February 22, 2022; online publish-ahead-of-print May 24, 2022.

Dr Sasaki is a plastic surgeon in private practice in Loma Linda, CA, USA.

Corresponding Author:
Dr Gordon Sasaki, 800 Fairmount Avenue Suite #319 Pasadena, CA 91105, USA.
E-mail: ghsasakimd@drsasaki.com

Presented at: The 18th International Federation for Adipose Therapeutics and Science Annual Meeting in November 2021, Ft. Lauderdale, FL, USA; and the International Congress on Adipose Stem Cell Treatments Annual Meeting in December 2021, Genolier, Switzerland.
Male and female pattern loss of hair is a prevalent disorder often with early onset that can lead to significant psychosocial effects in both sexes. Regardless of the etiological factors in play, the pathological changes appear nearly identical in males and females and include, but not limited to, shortened anagen phases and progressive follicular miniaturization in subsequent catagen/telogen stages. With the burden of genetic transmission and the presence of environmental stresses, these latent follicular remnants may further advance to exogen shedding and kenogen deletion, leading to an irretrievable reduction of thickness, density, and total number of hairs. Although male pattern hair loss (MPHL) is believed to be due to a polygenic mode of inheritance and presence of dihydrotestosterone (DHT), the precise biomolecular mechanisms are unclear. Female pattern hair loss (FPHL) has remained a poorly understood complex in which a number of factors, such as heredity, androgen-dependency and other hormonal effects, inflammation, immunological diseases, drugs, acute stress, diet, significant weight changes, and partum, continue to be investigated. Follicular unit extraction surgery remains the gold standard treatment for advanced MPHL and FPHL as a stand-alone therapy because viable anatomically intact follicles are transplanted from genetically protected sites to alopecic areas. In contrast, medical treatments are believed to promote neogenesis or rescue of dormant hair follicles in susceptible areas of the scalp whose eventual fate might be one of thinning and loss. FDA-approved drugs, such as finasteride, which modulate androgen metabolism, or minoxidil that promote hair growth, have limited success rates, suggesting that additional pathogenic pathways may be at play that require poly-therapies and prolonged treatments for lasting results.

For over 20 years, culture and animal follicle studies have demonstrated that paracrine communicators, emanating from stem cell domains, not only play critical roles in defining cell identity, self-renewal, differentiation, and migration during de novo follicle morphogenesis but also regulate recapitulation of its embryonic development during postnatal growth, miniaturization, and restoration. Knowledge of these cellular and molecular regulators has provided insights for the development of innovative stem cell clinical trials and therapies in the field of regenerative medicine to address human aesthetic and diseased hair restoration. Current investigations and clinical protocols have focused enthusiastically on the use of adipose-derived stem cells (ADSCs), platelet particles in platelet-rich plasma (PRP) and isolated biologic products in conditioned media to promote neogenesis of new follicles, stimulate the transition from telogen to anagen, and recover apoptotic follicles. The putative mechanisms of action are directly related to the myriad of growth factors, cytokines, and other active cellular biological molecules that orchestrate hierarchical signaling and transcriptional cross-talk from domains in the dermal papilla.
to proximal follicular stem cell niches (bulge) and their corresponding receptors downstream in the secondary hair germ and matrix. Ultimately gene-expression factors promote hair growth and regeneration of preferred cell populations within normal postnatal or miniaturized follicles.

Extracellular vesicles (EVs) are being investigated through clinical trials and studies because their diverse released bioactive molecules are vital for intercellular communications and display similar paracrine effects as growth factors and cytokines discharged from mesenchymal stem cells (MSCs) and PRP (Figures 1, 2). The responses include cellular proliferation and differentiation, angiogenesis, immuno-modulation, and regulation of inflammation all of which have potential therapeutic uses in cardiovascular diseases, muscle-cartilage-bone diseases, wound healing, hair loss, and other diseases. Although hair restoration surgeons are citing impressive and safe results with EV treatments for hair restoration, no evidence-based data have been published. The use of EVs biologicals, as a cell-free therapy, has recognized advantages over cell-based therapies that include allogenic usage, superior safety profile, less immunogenicity, “off-the-shelf” strategy, stability, and scalability.

The applications of stem cell and non-cell therapies in regenerative aesthetic medicine continue to be confusing for physicians because of ill-defined, misunderstood, and often misleading information in this evolving field of medical practice. On May 31, 2021, the US FDA enacted a policy change that all allogeneic stem cell therapies and their biologic products are regulated under the Federal Drug and Cosmetic Act Section 351 and are not approved for clinical use without an approved IRB, Investigational New Drug Application (IND), and a Biologic License Application (BLA). This retrospective clinical case study was completed before the FDA’s decision under the auspices of a retrospective IRB to investigate this product’s safety and efficacy in hair restoration.

METHODS

Study Design

The study considered over 65 male and female candidates in the author’s (G.H.S.) private practice from which subjects were selected who met inclusion (Table 1) and exclusion (Table 2) criteria. Selected subjects were enrolled in this retrospective open-label, nonblinded, nonrandomized, investigator-initiated primary safety and efficacy trial from February 14, 2020, to April 21, 2021. The study protocol was reviewed and approved by the IRB of the Institute of Regenerative and Cellular Medicine (Protocol number: SA-EXO-001, Approval Number: IRCM-2021-292, May 12, 2021). Patients signed informed consents that complied with the standards of the Bill of Rights, in accordance with the Declaration of Helsinki, the Health Insurance Portability and Accountability Act (HIPPA). By signing the provided written consent and release forms, patients also agreed to the use and analysis of their data for presentation and publication. All adverse outcomes were reviewed by the IRB oversight board. Each patient received an initialed copy of their consent forms and protocol. Patients were informed of their financial responsibilities by participation in the study. During the final evaluation period of at least 6 months, each subject’s response was defined as “worse” (progression of hair loss, density, and thinning), “stable” (no change in hair loss, density, or thinning), or “growth” (observed or trichoscan-measured improvement in hair growth, density, and thickness). The basis for grouping clinical responses into these categories was based on the assessment of blinded global photographs, trichoscans, and questionnaires.

Assessment Criteria

Body Mass Index

The total body fat was analyzed by applying the Futrex Light Wand (Hagerstown, MD) at a standardized point on the mid-point of the bicep muscle by a single technician (Margaret Gaston) (Table 3). The near-infrared light beam’s level was computed to reflect the overall body fat level, based on age and gender. The correlation coefficient of percent body fat as predicted by the Futrex near-infrared method was 0.94 (P < 0.01). The average of 3 measurements provided the final changes in the percentage of total body fat and BMI values throughout the study.

Standardized Photography and Trichoscans

All photographs were taken with a high-quality digital 16 MAGA-PIXELS high-resolution camera and color macros-lens that provided 12× and 36× magnification for macro-hair images at standardized angles, positions, and distances in the same room against a solid backdrop with tangential lighting to highlight features (External Medical Camera, CAFLYL Institute, Los Angeles, CA). All photographs were compiled by removal of identifying information before their assessment. Each of 3 blinded evaluators was instructed to judge unlabeled pretreatment and posttreatment photographs of each patient’s scalp for changes in hair density and growth patterns. The evaluation in each scalp was scored as “improvement (mild, modest),” “no change,” or a “worsening” of hair density and growth coverage. Trichoscans were performed in all subjects by a trained technician with the use of Machine learning, computer vision algorithms for hair image processing, and the use of software application to automatically render diagnostic measurements of hair density, follicle diameter, and terminal/veilus hairs within a 0.8-cm² located at the frontal hairline, mid-scalp, and crown with the same External Medical Camera System. All hairs with a diameter of
**Table 1. Inclusion List**

| Characteristics                                                                 |
|---------------------------------------------------------------------------------|
| Males and females, aged 18–80 years and in good health.                           |
| Male Pattern Hair Loss (MPHL) Grades III to IV based on Norwood-Hamilton Scale |
| Female Pattern Hair Loss (FPHL) with early limited or diffuse hair loss consistent with Grades I–III based on the Ludwig Scale |
| Patients who experienced worsening responses or were in remission on minoxidil, finasteride, dutasteride, and spironolactone after a year on therapy and continued hair loss at least 6 months off medication(s). |
| Patients on supervised therapies consisting of estrogen/progesterone/testosterone/other pituitary replacement therapy or thyroid replacement therapy and experiencing hair thinning and loss on replacement therapies. |
| Patients who were treated with follicular unit extraction transplantation and experiencing hair thinning and loss in the transplanted and non-transplanted scalp a year after surgery. |
| Patients who experienced worsening responses or were in remission after platelet-rich plasma (PRP) treatment(s) after a year on therapy and continued hair loss at least 6 months off PRP treatment. |
| Patients who were treated with fat grafting, mechanically derived nanofat cells (SVF), or enzymatically derived SVF (LSVF) and were experiencing hair loss at least a year after the last treatment. |
| Absence of physical or psychological conditions unacceptable to investigator.       |
| Patients of childbearing potential who had a negative urine pregnancy test and were willing to use an acceptable method of birth control (barrier methods with spermicidal agent, hormonal methods, intrauterine device, and abstinence during the study). |
| Willingness and ability to provide written consent for study, photography, and HIPAA authorization before performance of any study-related procedure. |

**Table 2. Exclusion Criteria**

| Characteristics                                                                 |
|---------------------------------------------------------------------------------|
| Patients who have a diagnosis of telogen effluvium (generalized shedding of hair) or any cicatricial (burn scars) or inflammatory alopecia, or immunogenic-related alopecia (alopecia areata). |
| Patients who have a sensitive, irritated, or abraded scalp area.                 |
| Known allergic reaction to components of study treatment.                       |
| History of uncontrolled autoimmune disease, diabetes mellitus, or any cancer.   |
| Use of systemic agents that increase bleeding/clotting or disorders associated with these effects. |
| Clinically significant medical or psychiatric illness currently as determined by the investigator. |
| Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk. |
| Pregnant or lactating females; females trying to become pregnant.               |

**Table 3. Clinical Documentations**

| Determinants at baseline ($V_0$) and month-6 ($V_6$)                      |
|--------------------------------------------------------------------------------|
| BMI (kg/m²)                                                                  |
| Weight measurements (kg)/height measurements (m)                           |
| Standardized digital photography                                            |
| Computerized trichoscans                                                    |
| Subjective questionnaires                                                   |
| IGAIS (Investigator Global Aesthetic Improvement Scale)                     |
| PGAIS (Patient Global Aesthetic Improvement Scale)                         |

$>40 \ \text{µm}$ were categorized as terminal hair, and all hairs with lesser diameter were categorized as vellus hairs. An independent technician outside the office performed the calculated measurements from each site which were averaged to provide final numbers that compared the effects between baseline ($V_0$) and month-6 ($V_6$).

**Satisfaction Questionnaires**

Secondary endpoints included investigator and patient assessments of global and hemi-scalp changes in hair density and thickness at baseline and follow-up visits. For each patient, paper surveys were identified by a unique number and evaluation date and distributed as a batch before the starting date. Each patient was asked to fill out their surveys in the privacy of their homes before their evaluation sessions. The investigator filled out his assessment for each patient in privacy after each evaluation session. The registered nurse collected all subject and investigator surveys which were calculated at the end of the study by the statistician utilizing the designated identification number for each patient on a 6-point satisfaction scale for the entire scalp (Table 4).

**Extracellular Vesicles Product**

XoFlo (Direct Biologics, LLC, Austin, TX) is an aseptic human bone marrow mesenchymal stem cell–derived EV isolate. The donated human bone marrow tissue allograft is a minimally manipulated single-donor-per-lot tissue product and
contains no animal products, chemicals, or drugs, and is manufactured under strict cGMP guidelines for the absence of communicable diseases in the processing and isolation of the product. XoFlo is marked solely for homologous use and packaged as a frozen solution in 1-, 2-, and 5-mL vials. ExoFlo, the same product designated as XoFlo in this study, is labeled for only COVID clinical trials that are currently being conducted and FDA-approved under Investigational New Drug (IND) #: 21669 by its manufacturer, Direct Biologics.

### Surgical Technique

Surgery was performed under local anesthesia in an office operating suite. Preoperative dots with a marking pen outlined the regional distribution of hair loss or thinning, such as in the frontal-temporal zones, mid-scalp, and crown areas. An aseptic preparation was performed with the application of isopropyl alcohol solution (70%). An anesthetic ring block with 0.5% lidocaine-containing epinephrine (1:200,000), buffered with 8.4% sodium bicarbonate solution (8:2 ratio), was infiltrated in the subdermal plane using a 30-gauge needle attached to a tuberculin syringe. The average total volume injected varied between 5 to 7 mL. With this technique, the surgical field was maintained with less bleeding from subsequent microneedling. The content in the frozen vial was thawed at room temperature within 10 minutes and withdrawn into a larger syringe in which bacteriostatic 0.9% normal saline was added to the original XoFlo volume as needed in ratios ranging from 1:2 up to 1:10. This diluted volume allowed sufficient treatment of XoFlo from smaller to larger areas of the scalp. The author preferred to use undiluted 2 or 5 mL volumes so that the highest number of EVs was localized to treat alopecic areas.

The XoFlo preparation was loaded into separate 1-mL tuberculin syringes to which was attached a 32-gauge short needle. Approximately 0.08 to 0.1 mL was deposited in the intradermal plane at each dot from which an estimated spread of solution up to 2.5 cm of the solution was anticipated. Light scalp massaging further distributed the EV solution more evenly throughout the scalp. Patients, who consented to 2.5-mm microneedling (SkinPen, Crown Aesthetics, Dallas, TX) over the entire treated scalp, received 2 to 3 passes with the stamping technique to produce visible blood staining at the openings. The scalp was washed with warm sterile water and towel-dried. Patients, who consented to a 678-nm Low-Level Light-Therapy (LLLT) light treatment from an FDA-cleared laser diode helmet device (TheraDome LH80, Pleasanton, CA), were immediately treated for a single 20-minute session. Patients were recommended to continue their previous scalp medications or topicals to reduce any anticipated withdrawal shock of their hair into quiescent phases.

### RESULTS

Baseline characteristics of male and female subjects treated over a 13-month period in an open-labeled, nonblinded, nonrandomized, retroactive IRB-approved safety and efficacy trial.

### Baseline Patient Characteristics

Baseline demographics and clinical characteristics are reported in Table 5. Nine males (average age: 43.3 years; range, 27-76 years) and 22 females (average age: 62.9 years; range, 28-80 years) were treated.

| Demographics | Female | Male |
|--------------|--------|------|
| Number       | 22     | 9    |
| Average age (range, years) | 62.9 (28-80) | 43.3 (27-7) |
| Average BMI (range, kg/m²) | 22.7 (18.6-35.1) | 25.1 (19.6-28.9) |

| Ethnicity   | Female | Male |
|-------------|--------|------|
| Middle-Eastern | 0      | 1    |
| Hispanic    | 2      | 0    |
| Asian       | 5      | 1    |
| Caucasian   | 15     | 7    |

| Classification | Female | Male |
|----------------|--------|------|
| Norwood-Hamilton | n/a    | III (6) |
| Ludwig | I-3 (1) | n/a |
|       | II-1 (13) | |
|       | II-2 (5) | |
|       | III (3) | |

### Table 5. Clinical Demographics

Baseline characteristics of male and female subjects treated over a 13-month period in an open-labeled, nonblinded, nonrandomized, retroactive IRB-approved safety and efficacy trial.

### Table 6. Age Influence on XoFlo (Direct Biologics, LLC, Austin, TX) Responses

Table 6. Age Influence on XoFlo (Direct Biologics, LLC, Austin, TX) Responses

| No. and sex of patients | Age (years) | Worse (no.) | Stable (no.) | Growth (no.) |
|-------------------------|-------------|-------------|--------------|--------------|
| 22 females              |             |             |              |              |
| 20                      | —           | —           | 1 (++)       |
| 30                      | —           | —           | —            |
| 40                      | —           | —           | —            |
| 50                      | 1           | 1           | 3 (++)       |
| 60                      | —           | 3           | 6 (+)        |
| 70                      | —           | 3           | 2 (+)        |
| 80                      | —           | —           | —            |
| %                       | 9.0%        | 36.4%       | 54.5%        |
| 9 males                 |             |             |              |              |
| 20                      | —           | —           | 1++++        |
| 30                      | —           | —           | 2++          |
| 40                      | —           | —           | 2++          |
| 50                      | —           | —           | 1++          |
| 60                      | —           | —           | —            |
| 70                      | —           | —           | 2+           |
| 80                      | —           | —           | —            |
| %                       | 0%          | 11.1%       | 88.9%        |

Patients, who consented to 2.5-mm microneedling (SkinPen, Crown Aesthetics, Dallas, TX) over the entire treated scalp, received 2 to 3 passes with the stamping technique to produce visible blood staining at the openings. The scalp was washed with warm sterile water and towel-dried. Patients, who consented to a 678-nm Low-Level Light-Therapy (LLLT) light treatment from an FDA-cleared laser diode helmet device (TheraDome LH80, Pleasanton, CA), were immediately treated for a single 20-minute session. Patients were recommended to continue their previous scalp medications or topicals to reduce any anticipated withdrawal shock of their hair into quiescent phases.

### Baseline Patient Characteristics

Baseline demographics and clinical characteristics are reported in Table 5. Nine males (average age: 43.3 years; range, 27-76 years) and 22 females (average age: 62.9 years; range, 28-80 years) were treated.
range, 28-87 years) were treated from November 3, 2020, to April 21, 2021. None of the 31 patients were excluded for protocol infractions or COVID-19 infections. Patients maintained their weights within 1 to 5 pounds throughout the 6-month study from their baseline BMIs: males (average BMI: 25.1 kg/m²; range, 19.6-28.9) and females (average BMI: 22.7 kg/m²; range, 18.6-35.1). Percentages of patients by race were 71% Caucasian, 20% Asian, 6% Hispanic, and 3% Middle-Eastern. Years of alopecia experienced in males (average 9.4 years; range, 3-20 years) and females (average 7.2 years; range, 1-25 years) were estimated based on recollection. The Norwood-Hamilton classification for MPHL ranged from III (6 patients) and IV (3 patients), while Ludwig classification for FPHL ranged from I-3 (1 patient), II-1 (13 patients), II-2 (5 patients), and III (3 patients).

### Age Influence on XoFlo Response

Although 20 female patients between 20 and 80 years of age demonstrated either growth (12/22 patients) or stable maintenance (8/22 patients) of hair density after a single XoFlo treatment, the greatest number clustered around 50 to 70 years of age (Table 6). Two female patients (38 years old; 59 years old) reported progressive hair loss after treatment (see next section below). Although 9 male patients between 20 and 70 years demonstrated either growth (8/9 patients) or stable maintenance of hair loss (1/9 patients) after a single XoFlo, most responders were between 20 and 50 years of age.

### Potential Factors for ExoFlo Failures

Two female patients demonstrated progressive loss of hair density and growth after receiving a variety of FDA-approved and other drugs for hair loss. The 38-year-old patient with over 10 years of alopecia responded neither to combination therapy of 4 drugs over 5 years nor later to 4 sessions of platelet-rich plasma (PRP) treatments while on spironolactone and dutasteride medications (Table 7). Each patient was asked to discontinue any hair loss treatments a year before initiating a single XoFlo treatment. Both patients were observed to be poor responders to XoFlo therapy from serial protocol evaluations and trichoscan measurements every 3 months for a year. Patients continued treatments for severe hormonal imbalances and major stress disorders during all hair stimulation therapies.
Influence of Duration of Alopecia on XoFlo Response

Thirteen female patients with less than 7-year history of alopecia demonstrated either growth (9/22) or stable maintenance (4/22) of their hair density after a single XoFlo treatment Table 8. Moreover, a lesser number of female patients with over 10 years of hair loss were still capable of either hair growth (3/22) or maintenance (4/22) after treatment. In 2 patients, the wide differences in durations of alopecia (1 and 10 years) did not appear to play a significant role in predicting outcomes because other adverse factors may have contributed to the “worse” results after XoFlo treatment. In MPHL, the impact that duration of alopecia plays may be clearer than that observed in FPHL. In this study, 7 of 9 male patients with less than 8-year history of alopecia and a briefer time for hair loss exhibited increased hair growth and density after treatment. However, 2 male patients with over a 20-year history of hair loss also noticed stable maintenance of their alopecia but not growth after treatment.

Influence on Stage of Alopecia on XoFlo Response

The clinical staging of alopecia may not necessarily correspond with the duration of alopecia because of the unpredictable rate and proportion of hair loss that are often observed from early hair thinning to recognizable patterns of obvious hair loss in male and female pattern alopecia Table 9. Despite these characteristic occurrences, 9 of 22 female patients with early Ludwig stages of hair loss (I-3, II-1) and only 3 of 22 patients with more advanced stage-II-2 pattern alopecia observed hair growth and increased density after treatment, while 8 other patients with Ludwig II-1 to extensive diffuse Ludwig stage III of hair loss were found to have stable maintenance of hair loss after one treatment. As previously mentioned, 2 female patients with extensive Ludwig III stages of hair loss and associated adverse medical factors experienced “worse” results after XoFlo treatment. On the other hand, 8 of 9 male patients with early stages of Norwood-Hamilton pattern hair loss (III-IV) exhibited increased hair growth and density, while the remaining patients (Norwood-Hamilton III) experienced stable maintenance of hair loss after a single treatment. Although the data suggest that there may be a potential advantage in treating earlier rather than advanced stages of MPHL or FPHL, further multicentered studies with a larger number of patients, wider range of alopecia, and longer follow-ups will be required to substantiate these preliminary findings.

Influence of XoFlo Volume (mL) on Response

A greater hair growth response can be anticipated when a greater number of paracrine factors are made available after the administration of larger volumes of EVs (Table 10). Although 12 of 22 females exhibited increased hair growth and density, the fraction that received 5-mL ExoFlo observed a larger amount of hair growth, follicle diameter, and density than those treated between 2 and 4 mL of ExoFlo. Furthermore, 8 of 22 patients observed stabilization of their hair loss after receiving either 2, 3, or 5 mL of ExoFlo. It is speculated that the 2 female patients who were worse after treatment had other unfavorable medical factors that possibly worked against a positive paracrine outcome. Six of 9 male patients, who were treated with volumes 5, 7, and 8 mL, responded with more hair growth than that observed in 2 other patients treated with 1 to 2 mL of ExoFlo. One male, who received 2 mL of XoFlo, demonstrated less shedding and more stabilization of hair loss. The preliminary data suggest again that the use of larger rather than smaller volumes of ExoFlo resulted in more predictable and robust outcomes of hair density in MPHL and FPHL.

Influence of Dilution of XoFlo on Response

Although the total amount of paracrine factors remains the same regardless of its dilution with normal saline, the
delivery of a greater concentration of exosomes in a full-strength volume is anticipated to produce a superior response in a fixed area of alopecic scalp (Table 11). In this manner, 11 of 22 female patients observed greater hair growth and density with either undiluted or a 1:2 diluted solution, while 1 patient responded with lesser growth after a 1:4 dilution treatment. Moreover, stable maintenance of hair loss was reported in 8 other patients who received undiluted XoFlo or dilutions ranging from 1:2 to 1:5. The abovementioned 2 female patients, who experienced worsening outcomes, received either 1:2 dilution or undiluted 5 mL of XoFlo. Eight male patients who received either undiluted (6/9) or 1:2 dilution (2/9) responded with a robust increase in hair density and diameter, while only 1 patient reported stable maintenance of hair loss after receiving a 1:2 dilution of XoFlo. Once again, the application of pure or minimally diluted solutions rather than higher mixtures predictably yielded greater hair growth and density in MPHL and FPHL patients.

**Table 10. Potential Influence of Concentration of Extracellular Vesicles/Undiluted Volumes of XoFlo (Direct Biologics, LLC, Austin, TX) on Responses to Treatment**

| No. and sex of patients | Influence of dilution ratios to XoFlo Effect | Worse (no) | Stable (no) | Growth (no) |
|-------------------------|---------------------------------------------|------------|-------------|-------------|
| Female                  | 22 females                                  | None       | 1           | 2           | 5           |
|                         | 1:2                                         | 1          | 1           | 2           | 6           |
|                         | 1:3                                         | —          | 2           | —           | —           |
|                         | 1:4                                         | —          | —           | 1           | —           |
|                         | 1:5                                         | —          | 2           | —           | —           |
| Male                    | 9 males                                     | None       | —           | —           | 6           |
|                         | 1:2                                         | —          | 1           | 2           | —           |
|                         | 1:3                                         | —          | —           | —           | —           |
|                         | 1:4                                         | —          | —           | —           | —           |
|                         | 1:5                                         | —          | —           | —           | —           |

That said, 7 female patients who experienced hair growth after topical minoxidil, finasteride, dutasteride, and spirronolactone treatments and were in remission for a year also responded to XoFlo, while 1 patient, who did not achieve any significant changes in hair density after minoxidil, noted less hair loss after XoFlo treatment. The above-mentioned 2 female patients, who experienced worsening effects after XoFlo, were reportedly unresponsive to hair stimulation drugs and were also resistant to the usage of intradermal steroids and oral methotrexate. In addition, both remained under medical care for severe stress and hormonal imbalances. Of interest, 4 females who were on effective therapies for medical diseases (Hashimoto’s disease, exophthalmos from hypothyroidism, diabetes mellitus, and hormonal imbalance) demonstrated at least stable maintenance of their hair loss after XoFlo treatment. One patient with diet-controlled diabetes melitus responded to treatment.

**Influence of Previous Drug and Disease Factors in Males on XoFlo Response**

Seven male patients who experienced hair growth with topical minoxidil or oral finasteride and dutasteride and were in remission for a year also responded to treatment (Table 13). One patient with controlled juvenile diabetes, who responded to the previous usage of minoxidil and then was observed to be in remission, exhibited hair growth after XoFlo treatment.

**Influence of Previous Surgical Procedures on XoFlo Response in Females**

It would be anticipated that patients who responded to paracrine factors in PRP would probably benefit from similar growth factors and cytokines in XoFlo (Tables 14, 15).
That said, 5 female patients, who demonstrated hair growth after 2 to 6 sessions of PRP and were in remission for a year, also exhibited increased hair density after ExoFlo treatments, while 2 patients who showed no response to PRP treatments reported less shedding after ExoFlo treatment. The previously mentioned female patient, who reported an increased loss of hair after 4 PRP sessions, also observed increased shedding after XoFlo treatment. Another patient, who responded with increased hair density after 1 session of fat grafting and PRP to her scalp 3 years before and thereafter exhibited hair loss, also noticed increased hair density after XoFlo treatment. Four of 9 male patients who benefitted from 3 to 6 sessions of PRP but were in remission for a year demonstrated increased hair density after a single XoFlo treatment. Of the 2 male patients who had undergone previous follicular unit extraction (FUE) hair transplantations, and increased hair growth after fat grafting and PRP treatments at least 3 years before and in remission, 1 reported increased hair density after XoFlo treatment, while the other male exhibited less hair loss after XoFlo treatment.

### Table 12. Influence of Previous Drug and Disease factors in Females on XoFlo (Direct Biologics, LLC, Austin, TX) Responses

| Influence of drug factors to XoFlo effect | Worse | Stable | Growth |
|-----------------------------------------|-------|--------|--------|
| Minoxidil (positive response)           | —     | —      | 4      |
| Minoxidil (minimal to no response)      | 2     | 1      | —      |
| Finasteride (positive response)         | —     | —      | 1      |
| Finasteride (minimal to no response)    | 2     | —      | —      |
| Dutasteride (positive response)         | —     | —      | 1      |
| Dutasteride (minimal to no response)    | 1     | —      | —      |
| Spironolactone (positive response)      | —     | —      | 1      |
| Spironolactone (minimal to no response) | 1     | —      | —      |
| Steroid/Methotrexate                    | 1     | —      | —      |
| Hashimoto’s disease                     | —     | 1      | —      |
| Hypothyroidism (Exophthalmos)           | —     | 1      | —      |
| Diabetes Mellitus                       | —     | 1      | 1      |
| Hormonal Imbalance (severe HRT)         | 2     | 1      | —      |
| Major stress                            | 2     | —      | —      |

HRT, hormone replacement therapy.

### Table 13. Potential Responses in Males to Previous Medications for Hair and Presence of Diseases Known to Affect Hair on Responses to XoFlo (Direct Biologics, LLC, Austin, TX) Treatment

| Drug factors | Worse | Stable | Growth |
|--------------|-------|--------|--------|
| Minoxidil (positive response) | —     | —      | 5      |
| Minoxidil (minimal to no response) | —     | —      | —      |
| Finasteride (positive response)   | —     | —      | 3      |
| Finasteride (minimal to no response) | —     | —      | —      |
| Dutasteride (positive response)   | —     | —      | 3      |
| Dutasteride (minimal to no response) | —     | —      | —      |
| Disease factor | —     | —      | —      |
| Diabetes mellitus                  | —     | —      | 1      |

### Trichoscan Measurements

At 6 months, trichoscans were performed in 7 female and 4 male patients who responded to treatment. The percent changes from baseline in hair density, terminal hair density, vellus hair density, and follicle diameter were analyzed at the frontal-temporal scalp, mid-scalp, vertex, and control occipit. Increases in percent change in hair densities (11.1%-24.2%), terminal hair densities (16.4%-45.5%), vellus hair densities (18.4%-36.4%), and follicle diameter (9.4%-32.3%) were most consistently measured in the frontal-temporal scalp and least in the occipital scalp.

Trichoscans at 6 months were also done in 3 female and 1 male patient, who observed no significant change or experienced hair loss after treatment (data not shown). The percent changes from baseline in hair density (-1.6% to +5.3%), terminal hair density (-3.4% to +3.3%), vellus hair density (-5.1% to +1.7%), and follicle diameter (-5.3% to +4.6%) were consistently below percent changes in the occipital region (8.7% to 15.8%). The quantitative data from these 15 patients need confirmatory measurements from a larger cohort to validate these preliminary observations.

### Global Questionnaire Assessments

Patients and investigator completed the satisfaction questionnaires at baseline and month 6 on a 6-point scale (Table 18). Each subject’s Patient Global Aesthetic Improvement Scale (PGAIS) value closely aligned with Investigator Global Aesthetic Improvement Scale (IGAIS) determination at both evaluation periods. Of the 22 female patients, 2 remained “very dissatisfied,” 8 observed “satisfied,” and 12 were “very satisfied” with their results. Of the 9
male patients, 1 remained “dissatisfied,” 5 were “satisfied,” and 3 were “extremely satisfied” with their treatments.

**Tolerability and Safety**

Patients did not experience significant adverse events such as fever, myalgias, chills, and fatigue. Transient swelling and localized pain to the scalp for a day were most likely from microneedling at a depth to produce bleeding at the entry points. No scalp cellulitis occurred after the procedure. Patients were not treated prophylactically with oral antibiotics or pain medications. They were advised to shower the day after the procedure with their usual shampoo. Patients returned to their normal physical activities within 24 hours.

**DISCUSSION**

Stem cells and their products have shown promise for hair restoration based on their paracrine signaling in regulating hair cycling, reactivation of quiescent miniaturized follicles, de novo formation of new follicles, and reversing the course of apoptotic follicles. Although the precise bioactive molecules that synchronize discrete stem cell populations within the follicle to be active, quiescent, stimulatory, or inhibitive are unknown and they primarily consist of pivotal growth factors, cytokines, messenger RNAs, and microRNAs secreted by specialized follicular stem cells, extrinsic mesenchymal, and hematogenous stem cell sources. The earliest strategy of using ADSCs, bone marrow-derived regenerative cells, or PRPs to restore hair growth may not be the cells themselves but their secreted factors. In fact, recent investigations have begun to focus on the clinical applications of secretomes, as a cell-free alternative to stem cell-based approaches because they possess significant advantages over cell-based therapies. The second strategy employed the use of secretomes, obtained from conditioned media of cultured ADSCs, which not only provided salutary paracrine effects on neighboring wound healing cells by their angiogenic, hematopoietic, anti-apoptotic, fibroblastic, and pro-inflammatory properties but also directly impacted follicular growth.

In the past 3 decades, the third approach by which stem cells act in a paracrine fashion has emerged that involves the intercellular transfer of EVs, one of which has been identified as exosomes. Recent articles have described the status of isolation, characterization, molecular composition, and biogenesis of these lipid-lined sacs that contain a diverse number of growth factors, cytokines, micro-RNA, and messenger RNA. These bioactive molecules are known to modulate cell-cell communications for homeostasis, immune signaling, angiogenesis, inflammation, senescence, proliferation, and differentiation. As expected, EV effects in vitro and in animal studies were first observed in stem cell-conditioned media from deer antler mesenchymal stem cells, mouse-bone marrow mesenchymal cells, and ADSCs that increased Wnt3a mRNA expression in dermal papilla (DP) cells. Further investigations demonstrated that EVs isolated from DP cells increased proliferation and differentiation of cells in the DP matrix, outer root sheath cells, shaft elongation, and prolongation of the anagen phase. Although these preclinical investigations strongly suggested that EVs could promote hair follicle growth and development, there are currently no published clinical IRB-approved trials reporting on their safety and efficacy in humans except for preliminary presentations and a review article.

This retrospective open-label trial gathered additional information on the safety and efficacy of XoFlo treatments on 22 females and 9 males under a retrospective-approved IRB. The author accepted patients who complained of progressive hair loss and thinning or were disappointed by the results of previous medications or surgical procedures. To evaluate the safety of this new therapy, patients were cleared by their physicians of any health risks and were followed for any side effects or significant adverse reactions after previous medical treatments and to XoFlo injections. To evaluate the efficacy, the use of global photographs, trichoscans, and follow-up questionnaires were used to interpret results that may be influenced by the patients’ different ethnic backgrounds, ages, stage of classifications,

### Table 14. Influence of Surgical Factors on XoFlo (Direct Biologics, LLC, Austin, TX) Effects in Females

| Surgical factors to XoFlo effect | Worse | Stable | Growth |
|----------------------------------|-------|--------|--------|
| Platelet-rich plasma (PRP)       |       |        |        |
| 1 session                        |       | 1      | 1      |
| 2 sessions                       |       |        | 1      |
| 3 sessions                       |       | 1      |        |
| 4 sessions                       | 1     | 1      | 1      |
| 5 sessions                       | 1     | 1      | 1      |

### Table 15. Influence of Surgical Factors on XoFlo (Direct Biologics, LLC, Austin, TX) Effects on Males.

| Influence of surgical factors to XoFlo effect | Worse | Stable | Growth |
|----------------------------------------------|-------|--------|--------|
| Platelet-rich plasma (PRP)                   |       |        |        |
| 1 session                                    |       |        |        |
| 2 sessions                                   |       |        |        |
| 3 sessions                                   |       |        | 1      |
| 4 sessions                                   |       |        | 1      |
| 5 sessions                                   |       |        | 1      |
| 6 sessions                                   | 1     | 1      | 1      |

Hair transplantation + fat grafting + PRP

**Aesthetic Surgery Journal Open Forum**
durations of alopecia, responses to previous treatments or impact of coexisting disease factors, the amount of delivered XoFlo, and finally the effects of wound healing from microneedling. Because of the small sampling numbers and short evaluations between 6 months to a year, however, provisional conclusions were speculatively defined as “worse,” “stable,” or “growth” trends from baseline values.

A binary treatment response of reduced shedding or increased hair growth was observed in females over the age of 50 years and in males under the age of 50 years. The reasons for this age dichotomy were unclear. Several studies have suggested that males significantly responded to PRP treatments with a lesser effect than females. This gender-specific effect might be due to significant multifactorial conditions observed in especially younger females related to hair loss, which included oral contraceptive medications, premenopausal status, postpartum hormonal imbalances, dietary changes, thyroid and pituitary abnormalities, and environmental stresses. The higher number of growth responses to XoFlo in both female and male patients occurred with shorter histories of alopecia < 8 years or earlier Norwood-Hamilton/Ludwig stages of hair loss. This observation may be anticipated because of the greater amount of irretrievable hair loss that needed to be reversed in the advanced stages of alopecia. Furthermore, the use of larger, as well as undiluted volumes of XoFlo, tended to result in growth or stable maintenance of hair loss in higher numbers of male or female patients. This outcome might be due to the provision of greater numbers of EVs at each injection site. The growth responses to approved medications for hair growth, such as minoxidil or finasteride, might serve to be indicators for a similar response to exosomes as both have been shown to increase the activity of stem cell activities within the dermal papilla and bulge domains. Similarly, patients who exhibited hair growth after a series of PRP sessions would be more likely to respond to exosome treatments since similar biomodulators were involved in their paracrine effects. The presence of entities known to have a negative impact on hair growth such as autoimmune diseases, endocrine imbalances and diseases, and severe stress disorders was speculated to contribute to poorer outcomes after EV treatments and deserve to be further studied. Lastly, the effects of microneedling at a 2.5-mm needle depth resulted in mixed and inconclusive results in both female and male patients. The effects of microneedling in their wound-healing capacity might be insufficient to augment the beneficial effects of EVs. Most patients observed hair growth between the third to sixth months and did not require a booster session after a year. This study did not specifically address whether hair growth and increased density resulted from prolonging the anagen phase, shortening the telogen quiescent phase, facilitating transitions from vellus hairs, rescuing dormant exogen hair, or stimulating the formation of de novo hair follicles.

Trichoscan measurements were obtained in 15 of the 31 patients. Results showed that average hair densities, terminal hair densities, vellus hair densities, and follicle diameters at the 6-month follow-up period were greater than that observed in the control occipital area in patients that clinically responded to treatment. On the other hand, 4 patients that were found to have minimal to no response to treatment also had lower average percent changes in comparison to the average percent changes in the control occipital site. The remaining 16 patients in the study were unable to have their final trichoscan evaluations because of the pandemic shutdown.

Most patients, including the investigator, assessed their results as “satisfied” to “very satisfied” after a single treatment. Longer follow-ups may determine whether a booster is required to increase and sustain their hair density over time.
CONCLUSIONS
This retrospective IRB-approved exosome study demonstrated preliminary promising and safe results on the treatment of female and male hair loss. The importance of demographic factors, medical conditions, responses to previous hair treatments, and methodologies in protocol design has yet to be determined as indicators to predict responses from therapy. Further multi-center IRB trials with larger numbers, standardized protocols, and longer follow-ups are needed to assess the safety and efficacy of this new therapy. Although the application of cell-free therapy over cell therapy has been discussed, there exist major hurdles that include the need for more evidence-based data to allow phased studies under FDA oversight and application for an Investigational New Drug status. Currently, all stem cell therapies and the use of their biologic paracrine products are not FDA approved and are under strict regulatory oversight.

Acknowledgments
The author wishes to thank Sharon Cuellar, CST, for surgical assistance; Melissa Avilea, MA, for IRB assistance; and Margaret Gaston, BS, for photographic assistance; Leon Ren, CEO, CAPILY Institute (Beverly Hills, CA), for assistance in trichoscan data gathering.

Disclosures
The author declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

Funding
The author received no financial support for the research, authorship, and publication of this article.

REFERENCES
1. Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53:708-728. doi: 10.1111/j.1749-6632.1951.tb31971.x
2. Olsen EA. Female pattern hair loss. In: Blum-Peytavi U, Tosti A, Whiting D, et al., eds. Hair Growth and Disorders. Springer; 2008:171-186.
3. Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26:929-931. doi: 10.1016/0190-9622(92)70134-2
4. Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia of women: comparisons with balding men and with female control subjects. J Am Acad Dermatol. 1993;29:568-575. doi: 10.1016/0190-9622(93)70223-g
5. Redler S, Messenger AG, Betz R. Genetics and other factors in the aetiology of female pattern hair loss. Exp Dermatol. 2017;26:510-517. doi: 10.1111/exd.13373
6. Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and 5α-reductase genes. J Invest Dermatol. 1998;110:849-853. doi: 10.1046/j.1523-1747.1998.00224.x
7. Gordon KA, Tosti A. Alopecia: evaluation and treatment. Clin Cosmet Investig Dermatol. 2011;4:101-106. doi: 10.2147/CCID.S10182
8. Leavitt M. Understanding and management of female pattern alopecia. Facial Plast Surg. 2008;24:414-417. doi: 10.1055/s-0028-1102905
9. Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol. 2011;52(2):81-88. doi: 10.1111/j.1440-0960.2011.00745.x
10. Hernandez BA. Is androgenetic alopecia a result of endocrine effects on the vasculature? Med Hypotheses. 2004;62:438-441. doi: 10.1016/S0306-9877(03)00342-6
11. Rassman WR, Berstein RM, McClellan R, et al. Follicular unit extraction: minimally invasive surgery for hair transplantation. Dermatol Surg. 2002;28:720-728. doi: 10.1046/j.1524-4725.2002.01320.x
12. Wu WY, Otberg N, Kang H, et al. Successful treatment of temporal triangular alopecia by hair restoration surgery using follicular unit transplantation. Dermatol Surg. 2009;35:1307-1310. doi: 10.1111/j.1524-4725.2009.01233.x
13. Bunagan MJ, Banka N, Shapiro J. Hair transplantation update: procedural techniques, innovations, and applications. Dermatol Clin. 2013;31:141-153. doi: 10.1016/j.det.2012.08.012
14. Uebel CO, Piccinini PS, Spencer LSB, et al. Female pattern hair loss: why the follicular unit transplantation surgical technique remains a good option. Plast Reconstr Surg. 2021;147:839-849. doi: 10.1097/PRS.00000000000027760
15. Trueb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37:981-990. doi: 10.1016/s0531-5565(02)00093-1
16. Paus R, Muller-Rover S, Van Der Veen C, et al. A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J Invest Dermatol. 1999;113:523-532. doi: 10.1046/j.1523-1747.1999.00740.x
17. Nowak JA, Polak L, Pasoli HA, et al. Hair follicle stem cells are specified and function in early skin morphogenesis. Cell Stem Cell. 2008;3:33-43. doi: 10.1016/j.stem.2008.05.009
18. Goldstein J, Valerie H. Home sweet home: skin stem cell niches. Cell Mol Life Sci. 2012;69(15):2573-2582. doi: 10.1007/s00018-012-0943-3
19. Kilroy GE, Foster S, Wu X, et al. Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol. 2007;212:702-709. doi: 10.1002/jcp.21068
20. Festa E, Fretz J, Berry R, et al. Adipose lineage cells contribute to the stem cell skin niche to drive hair cycling. Cell. 2011;146:761-771. doi: 10.1016/j.cell.2011.07.019
21. Schmidt B, Horsley V. Unraveling hair follicle-adipocyte communication. Exp Dermatol. 2012;21:827-830. doi: 10.1111/exd.12001
22. Coleman SR. Structural fat grafts: the ideal filler? Clin Plast Surg. 2001;28:111-119.
23. Dini M, Mori A, Quattrini Li A. Eyebrow regrowth in patient with atrophic scarring alopecia treated with an autologous fat graft. Dermatol Surg. 2014;40(8):926-928. doi:10.1111/dsu.0000000000000051

24. Amgar G, Greco J, Rinaldi F. Platelet-rich plasma and stem cells. In: Bouhanna P, Bouhanna E, eds. The Alopecias. CRC Press; 2016:195-210.

25. Perez-Meza D, Ziering C, Sforza M, et al. Hair follicle growth by stromal vascular fraction-enhanced adipose transplantation in baldness. Stem Cells Cloning. 2017;10:1-10. doi:10.2147/SCCAA.S131431

26. Cervelli V, Garcovich S, Bielli A, et al. The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: clinical and histomorphometric evaluation. Biomed Res Int. 2014;2014:760709. doi:10.1155/2014/760709

27. Gentile P, Garcovich S, Bielli A, et al. The effect of platelet-rich plasma on the treatment of androgenetic alopecia. Dermatol Surg. 2016;42(4):491-497. doi:10.1097/dss.0000000000000665

28. Rodrigues BL, Montalvao SAL, Cancela RBB, et al. Treatment of male pattern alopecia with platelet-rich plasma: a double-blind controlled study with analysis of platelet number and growth factor levels. J Am Acad Dermatol. 2019;80(3):694-700. doi:10.1016/j.jaad.2018.09.033

29. Sasaki GH. The effects of lower versus higher cell number of platelet-rich plasma (PRP) in hair density and diameter in androgenetic alopecia (AGA): a randomized, double-blinded placebo, paralleled group half-scalp IRB study. Aesth Surg J. 2021;41(11):NP1659–NP1672. doi:10.1093/ajss/jjab236

30. Gupta AK, Renaud HJ, Rapaport JA. Platelet-rich plasma and cell therapy. The new horizon in hair loss treatment. Dermatol Clin. 2021;39(3):429-445. doi:10.1016/j.det.2021.04.001

31. Pawitan JA. Therapy for severe COVID-19. Front Immunol. 2020;11:35. doi:10.3389/fimmu.2020.00608

32. Shinn H, Ryu Ho H, Kwon O, et al. Clinical use of conditioned media of adipose tissue-derived stem cells in female pattern hair loss: a retrospective case series study. Int J Dermatol. 2015;54(6):730-735. doi:10.1111/ijd.12650

33. Shinn H, Chong HW, Chung W-K, et al. Up-to-date clinical trials of hair regeneration using conditioned media of adipose-derived stem cells in male and female pattern hair loss. Curr Stem Cell Res Ther. 2017;12(0):1-7. doi:10.2174/1574888x12666170504120244

34. Lai RC, Chen TS, Lim SK. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med. 2011;6(4):481-492. doi:10.2217/rme.11.35

35. Johnny East DO, Trace Alexander DC, Dordevic M. IRB approved pilot safety study of extracellular vesicle isolate product evaluating the treatment of osteoarthritis in combat-related injuries. Stem Cell Res. 2020;1(2):1-10. doi:10.52793/JSCR.2020(1,2)-09

36. Lin A, Rodriguez NE, Zhao J, et al. Selective enrichment of microRNAs in extracellular vesicles produced by growth plate chondrocytes. Bone. 2016;88:47-55. doi:10.1016/j.bone.2016.03.018

37. Zhang B, Wang M, Gong A, et al. HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing. Stem Cells. 2015;33(7):2158-2168. doi:10.1002/stem.1771

38. Dong L, Hao H, Xia L, et al. Treatment of MSCs with Wnt/β-catenin signaling in male pattern promotes hair follicle regrowth. Sci Rep. 2014;4:5432. doi:10.1038/srep05432

39. Ramos R, Guerrero-Juarez CF, Plikus MV. Hair follicle signaling networks: a dermal papilla-centric approach. J Invest Dermatol. 2013;133:2306-2308. doi:10.1038/jid.2013.262

40. Stenn KS, Cotsarelis G. Bioengineering the hair follicle: fringe benefits of stem cell technology. Curr Opin Biotechnol. 2005;16:493-497. doi:10.1016/j.copbio.2005.08.002

41. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VE-GF-mediated angiogenesis. J Clin Invest. 2001;107:409-417. doi:10.1172/jci11317

42. Balana ME, Charreau HE, Leiros GJ, et al. Epidermal stem cells and skin tissue engineering in hair follicle regeneration. World J Stem Cells. 2015;7:711-727. doi:10.4252/wjsc.v7.i4.711

43. Rani S, Ryan AE, Griffin MD, et al. Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther. 2015;23(5):812-823. doi:10.1038/mt.2015.44

44. Sun B, Peng J, Wang S, et al. Applications of stem cell-derived exosomes in tissue engineering and neurological diseases. Rev Neurosci. 2018;29(5):531-546. doi:10.1515/revenuro-2017-0059

45. Gupta AK, Renaud HJ, Halaas Y, et al. Exosomes: a new effective non-surgical therapy for androgenetic alopecia? Skinmed. 2020;18:96-100.

46. Sengupta V, Sengupta S, Lazo A, et al. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev. 2020;29(12):747-754. doi:10.1089/scd.2020.0080

47. Hessvik NP, Llorent A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018;75:193-208. doi:10.1007/s00018-017-2595-9

48. De Jong OG, Van Valkom BM, Schifferers RM, et al. Extracellular vesicles: potential roles in regenerative medicine. Front Immunol. 2014;5:608. doi:10.3389/fimmu.2014.00608

49. Whitford W, Guterstam P. Exosome manufacturing status. Future Med Chem. 2019;11(10):1225-1236. doi:10.4155/fmc-2018-0417
52. US Food & Drug Administration. Jurisdictional Information. Updated April 9, 2020. https://www.fda.gov/combination-products/jurisdictional-information. Accessed July 22, 2021.
53. US Food & Drug Administration. Guidance, Compliance & Regulatory Information (Biologics). Updated May 2, 2022. https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics. Accessed July 22, 2021.
54. US Food & Drug Administration. Public Safety Notification on Exosome Products. Updated December 6, 2019. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products. Accessed July 22, 2021.
55. Bauer G, Elsallab M, Abou-El-Enein M. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-base interventions. Stem Cells Transl Med. 2018;7:676-685. doi: 10.1002/sctm.17-0282
56. Yuan A-R, Bian Q, Gao J-Q. Current advances in stem cell-based therapies for hair regeneration. Eur J Pharmacol. 2020;881:173197. doi: 10.1016/j.ejphar.2020.173197
57. Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regen Med. 2010;5(1):121-143. doi: 10.2217/me.09.74
58. Rendl M, Lewis L, Fuchs E. Molecular dissection of mesenchymal-epithelial interactions in the hair follicle. PLoS Biol. 2005;3(11):e331. doi: 10.1371/journal.pbio.0030331
59. Schmidt-Ullrich R, Paus R. Molecular principles of hair follicle induction and morphogenesis. Biossokay 2005;27:247-261. doi: 10.1002/bies.20184
60. Greco V, Chen T, Rendl M, et al. A two-step mechanism for stem cell activation during hair regeneration. Cell Stem Cell. 2009;4(23):155-169. doi: 10.1016/j.stem.2008.12.009
61. Hsu Y-C, Pasoli HA, Fuchs E. Dynamics between stem cells, niche and progeny in the hair follicle. Cell. 2011;144(1):92-105. doi: 10.1016/j.cell.2010.11.049
62. Sasaki GH. Review of human hair follicle biology: dynamics of niches and stem cell regulation for possible therapeutic hair stimulation for plastic surgeons. Aesthetic Plast Surg. 2019;43:253-266. doi: 10.1007/s00266-018-1248-1
63. Garza LA, Yang C-C, Zhao T, et al. Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. J Clin Invest. 2011;121(2):613-622. doi: 10.1172/JCI44478
64. Ohyama M, Terunuma A, Tock CL, et al. Characterization and isolation of stem cell-enriched human hair follicle progenitor cells. J Clin Invest. 2006;116:249-260. doi: 10.1172/jci26043
65. Gentile P, Scioli MG, Bielli A, et al. Stem cells from human hair follicles: first mechanical isolation for immediate autologous clinical use in androgenetic alopecia and hair loss. Stem Cell Investig. 2017;4:58. doi: 10.21037/sci.2017.06.04
66. Tsuboi R, Niyama S, Irisawa R, et al. Autologous cell-based therapy for male and female pattern hair loss using dermal sheath cup cells: a randomized placebo-controlled double-blinded dose-finding clinical study. J Am Acad Dermatol. 2020;83(1):109-116. doi: 10.1016/j.jaad.2020.02.033
67. Sasaki GH. Plastic surgery update on the biology of fat cells and adipose-derived stem cells for fat grafting. Open Access Lib J. 2015;2(e1505):1-26. doi: 10.17777/1090820x10373063
68. Kuga G, Epstein G. Isolation of adipose-derived stem cells: a primer. Hair Transpl Forum Int. 2020;30(5):194-195. doi: 10.1016/j.jdermsci.2018.08.004
69. Kuga G, Epstein J, Aronowitz J, et al. Cell enriched autologous fat grafts to follicular niche improves hair regrowth in early androgenetic alopecia. Aesthet Surg J. 2020;40(6):NP328-NP339. doi: 10.1093/asje/sjaa037
70. Tak YJ, Lee SY, Cho AR, et al. A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell constituent extract in androgenetic alopecia. Stem Cells Transl Med. 2020;9(8):839-849. doi: 10.1002/sctm.19-0410
71. Elmaadawi IH, Mohamed BM, Ibrahim ZAS, et al. Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. J Dermatolog Treat. 2018;29:431-440. doi: 10.1080/09546634.2016.1227419
72. Greco J, Brandt R. The effects of autologous platelet-rich plasma and various growth factors on non-transplanted miniaturized hair. Hair Transpl Forum Int. 2009;19(2):49-50. doi: 10.33589/19.2.0049
73. Li AI, Choi HI, Choi DK, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012;38:1040-1046. doi: 10.1111/j.1524-4725.2012.02394.x
74. Gentile P, Cole JP, Cole MA, et al. Evaluation of non-activated and activated PRP in hair loss treatment: role of growth factor and cytokine concentrations obtained by different collection systems. Int J Mol Sci. 2017;18:120. doi: 10.3390/ijms18020408
75. Stevens HP, Donners S, de Bruin J. Introducing platelet-rich stroma: platelet-rich plasma (PRP) and stromal vascular fraction (SVF) combined for the treatment of androgenetic alopecia. Aesthet Surg J. 2018;38(8):811-822. doi: 10.1093/asj/sjy029
76. Vizoso F, Eiro N, Cid S, et al. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017;18:1852. doi: 10.3390/ijms18091852
77. Whitford W, Guterstam P. Exosome manufacturing status. Future Med Chem. 2019;11(10):1225-1236. doi: 10.4155/fmc-2018-0417
78. Rehman J, Traktuev D, Li J, et al. Secretion of angiogenic, and antiapoptotic factors by human adipose stromal cells. Circulation. 2004;109(10):1292-1298. doi: 10.1161/01.cir.0000121425.42966.f1
79. Kim W-S, Park B-S, Sung J-H, et al. Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts. J Dermatol Sci. 2007;48(1):15-24. doi: 10.1016/j.jdermsci.2007.05.018
80. Fukuda H, Suga H. Hair regeneration treatment using adipose-derived stem cell conditioned medium. Follow-up with trichograms. Eplasty. 2015;15:e0.
81. Fukuoka H, Narita K, Suga H. Hair regeneration therapy: application of adipose-derived stem cells. *Curr Stem Cell Res Ther*. 2017;12(7):531-534. doi: 10.2174/1574888x1266617052214307
82. Narita K, Fukuoka H, Sekiyama T, et al. Sequential scalp assessment in hair regeneration therapy using an adipose-derived stem cell-conditioned medium. *Dermatol Surg*. 2020;46(6):819-825. doi: 10.1097/dss.0000000000002128
83. Yanez-Mo M, Diljander PR-M, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. *J Extracell Vesicles*. 2015;2015:1-60. doi: 10.3402/jev.v4.27066
84. Sasaki GH. Plastic surgery update on the mesenchymal stem-cell derived extracellular vesicles: towards cell-free therapeutic applications. *Open Access Lib J*. 2021;8(9):1-24. doi: 10.4236/oalib.1107393
85. Seo M, Kim JC, Kim HK, et al. A novel secretory vesicle from deer antlerogenic mesenchymal stem-cell-conditioned media (DAMSC-CM) promotes tissue regeneration. *Stem Cells Int*. 2018;2018:1-8. doi: 10.1155/2018/3891404
86. Rajendran RL, Gangadaran P, Bak SS, et al. Extracellular vesicles derived from MSCs activates dermal papilla cell in vitro and promotes hair follicle conversion from telogen to anagen in mice. *Sci Rep*. 2017;7:15560. doi: 10.1038/s41598-017-15505-3
87. Choi H, Choi E, Yoon S, et al. Effect of exosomes from human adipose-derived stem cells on hair growth. *J Extracell Vesicles*. 2019;8(Suppl 1):PF08.02. doi: 10.3389%2Ffcell.2020.574223
88. Kwack MH, Seo CH, Gangadaran P, et al. Exosomes derived from human dermal papilla cells promoted hair growth in cultured human hair follicles and augment the hair-inductive capacity of cultured dermal papilla spheres. *Exp Dermatol*. 2019;28:854-857. doi: 10.1111/exd.13927
89. Chen Y, Huang J, Chen R, et al. Sustained release of dermal papilla-derived extracellular vesicles from injectable microgel promotes hair growth. *Theranostics*. 2020;10:1454-1478. doi: 10.7150/thno.39566
90. Zhou L, Wang H, Jing J, et al. Regulation of hair follicle development by exosomes derived from dermal papilla cells. *Biochem Biophys Res Commun*. 2018;500:325-332. doi: 10.1016/j.bbrc.2018.04.067
91. Cooley JE. Bone marrow derived MSC exosomes for AA: the first 100 patients. Presentation presented at the International Society of Hair Restoration Surgeons World Congress, October 17-25, 2020; Virtual.
92. Zari S. The use of exosomes in the management of androgenetic alopecia/female pattern hair loss. Presentation presented at the International Society of Hair Restoration Surgeons World Congress, October 17-25, 2020; Virtual.
93. Gupta AK, Cole J, Deutsch DP, et al. Platelet-rich plasma for androgenetic alopecia: efficacy differences between men and women. *Dermatol Ther*. 2020;33(6):e14143. doi: 10.1111/dth.14143
94. Gupta AK, Bamimore MA, Foley KA. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses an assessment of evidence quality. *J Dermatolog Treat*. 2022;33(1):62-72. doi: 10.1080/09546634.2020.1749547